Developing a new class of engineered live bacterial therapeutics to treat human diseases
The role microbes play in human health and the ability of synthetic biology to engineer microbial properties opens up new ways of treating disease. In this perspective, the authors describe the design and development of these living therapeutics.
Guardado en:
Autores principales: | Mark R. Charbonneau, Vincent M. Isabella, Ning Li, Caroline B. Kurtz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/26fba4ca08df4eda919a1a6132d74277 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip
por: M. Tyler Nelson, et al.
Publicado: (2021) -
Engineering mammalian living materials towards clinically relevant therapeutics
por: Pedro Lavrador, et al.
Publicado: (2021) -
2D Nanosheets—A New Class of Therapeutic Formulations against Cancer
por: Ravichandran Manisekaran, et al.
Publicado: (2021) -
Managing Welfare and Antimicrobial-Resistance Issues in Treating Foot-and-Mouth Disease Lesions: A New Therapeutic Approach
por: Windsor P, et al.
Publicado: (2020) -
New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.
por: Robert H E Friesen, et al.
Publicado: (2010)